Sugi Predict

Sugi Predict / Compounds / SCHEMBL2824634

SCHEMBL2824634

SCHEMBL2824634

COc1cccc(S(=O)(=O)Nc2cccc(C(=O)Nc3ccc(C(=O)O)cc3)c2)c1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.70
▸ KMT2A Q03164 6/20 0.70
▸ LMNA P02545 2/20 0.69
▸ EGFR P00533 1/20 0.61
▸ FGFR1 P11362 1/20 0.61
▸ KDR P35968 1/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.60
▸ NPC1 O15118 2/20 0.60
▸ RAB9A P51151 2/20 0.60
▸ THRB P10828 1/20 0.60
▸ ALDH1A1 P00352 4/20 0.59
▸ MAPT P10636 3/20 0.59
▸ GAA P10253 1/20 0.59
▸ RECQL P46063 1/20 0.59
▸ TP53 P04637 1/20 0.57
▸ PKM P14618 1/20 0.57
▸ HPGD P15428 1/20 0.57
▸ MAPK1 P28482 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30600087 1.00 MEN1 (0.70) MEN1KMT2ALMNAEGFRFGFR1
SCHEMBL13532190 0.90 MEN1 (0.71) MEN1KMT2AEGFRFGFR1KDR
SCHEMBL2823113 0.90 TCF4 (0.67) MEN1KMT2ALMNAEGFRFGFR1
SCHEMBL13532193 0.89 MEN1 (0.74) MEN1KMT2ALMNASMN1; SMN2RAB9A
SCHEMBL5329582 0.87 PGR (0.71) MEN1KMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL2827105 0.87 MEN1 (0.67) MEN1KMT2ALMNATHRBALDH1A1
SCHEMBL2825284 0.87 LMNA (0.63) MEN1KMT2ALMNAEGFRFGFR1
SCHEMBL2825370 0.86 KMT2A (0.79) MEN1KMT2AEGFRFGFR1KDR
SCHEMBL13532171 0.84 MEN1 (0.77) MEN1KMT2ALMNASMN1; SMN2NPC1
SCHEMBL7824945 0.83 KMT2A (0.82) MEN1KMT2ASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232104-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS BLEICHER KONRAD (DE) 2012-09-13 — — US claimed
US-20110319438-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS BLEICHER KONRAD (DE) 2011-12-29 — — US claimed
US-20100144762-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS BLEICHER KONRAD 2010-06-10 — — US claimed
US-7723538-B2 enzyme inhibitors of membrane-bound carnitine-dependent palmitoyltransferases (CPTs); inhibit gluconeogenesis and therefore counteract hyperglycemia; 4-(3-Benzenesulfonylamino-benzoylamino)-benzoic acid HOFFMANN-LA ROCHE INC. (US) 2010-05-25 — — US claimed
EP-1891001-B1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS HOFFMANN LA ROCHE (CH) 2010-05-05 — — EP claimed
EP-1891001-A1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS F. Hoffmann-Roche AG (CH) 2008-02-27 — — EP claimed
WO-2006131452-A1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-12-14 — — WO claimed
US-20060276494-A1 Novel sulfonamides as L-CPT1 inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 — — US claimed
US-20240207270-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM WAVEBREAK INC (US) 2024-06-27 — — US disclosed
WO-2022212568-A9 COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM 1BASE PHARMACEUTICALS, LLC (US) 2023-11-16 — — WO disclosed
WO-2022212568-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM 1BASE PHARMACEUTICALS, LLC (US) 2022-10-06 — — WO disclosed
US-20120232104-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS BLEICHER KONRAD (DE) 2012-09-13 — — US disclosed
US-20110319438-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS BLEICHER KONRAD (DE) 2011-12-29 — — US disclosed
US-20100144762-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS BLEICHER KONRAD 2010-06-10 — — US disclosed
US-7723538-B2 enzyme inhibitors of membrane-bound carnitine-dependent palmitoyltransferases (CPTs); inhibit gluconeogenesis and therefore counteract hyperglycemia; 4-(3-Benzenesulfonylamino-benzoylamino)-benzoic acid HOFFMANN-LA ROCHE INC. (US) 2010-05-25 — — US disclosed
EP-1891001-B1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS HOFFMANN LA ROCHE (CH) 2010-05-05 — — EP disclosed
EP-1891001-A1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS F. Hoffmann-Roche AG (CH) 2008-02-27 — — EP disclosed
WO-2006131452-A1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-12-14 — — WO disclosed
US-20060276494-A1 Novel sulfonamides as L-CPT1 inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2006-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276494-A1 Novel sulfonamides as L-CPT1 inhibitors CPT1A, CPT1B, CPT2 MEN1 4442/4885KMT2A 1890/4885LMNA 3524/4885
US-20120232104-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS CPT1A, CPT1B, CPT2 MEN1 4442/4885KMT2A 1890/4885LMNA 3524/4885
US-20240207270-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM CPT2, PC, SREBF2 MEN1 4713/4885KMT2A 4386/4885LMNA 2122/4885
US-20100144762-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS CPT1A, CPT1B, CPT2 MEN1 4442/4885KMT2A 1890/4885LMNA 3524/4885
US-20110319438-A1 NOVEL SULFONAMIDES AS L-CPT1 INHIBITORS CPT1A, CPT1B, CPT2 MEN1 4442/4885KMT2A 1890/4885LMNA 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.